Kinetics and Organ Distribution of Allogeneic Natural Killer Lymphocytes Transfused into Patients Suffering from Renal Cell Carcinoma
- 1 June 2004
- journal article
- research article
- Published by Mary Ann Liebert Inc in Stem Cells and Development
- Vol. 13 (3), 307-314
- https://doi.org/10.1089/154732804323099235
Abstract
The transfusion of natural killer (NK) lymphocytes into patients suffering from malignant diseases is an approach of current interest in the field of immunotherapy. Little is known about the organ distribution, survival, and clearance of donor immune effector cells in cellular therapy, and no reports exist on these important parameters considering NK cells in particular or any other type of allogeneic lymphocytes in humans. In the context of a clinical Phase I/II study we examined the distribution of transfused allogeneic NK cells in patients suffering from renal cell carcinoma. The NK cells were ex vivo cultivated and activated before transfusion. To assess the circulation of the transfused cells in the peripheral blood, we used a nested PCR technique to detect HLA DRB1 alleles of the NK cell donors. Post-transfusion, all patients showed evidence of circulating donor cells for up to 3 days. After 7 days, all donor cells were cleared from the blood to undetectable levels. To assess organ distribution, 111In-labeled NK cells were injected and monitored by whole-body scintiscans. A distribution to the whole body, with preference for liver, spleen, and bone marrow, was observed after a short initial uptake in the lungs. No activity was observed in lymphatic nodes. A total of 2/4 evaluable metastases showed a clear accumulation of transfused NK cells. The half-life corrected activity in all body compartments remained almost constant over the 6-day observation period in concordance with the absence of any excretion of radioactivity. This may indicate an extended survival of the transfused cells, despite their foreign nature, in the host organism.Keywords
This publication has 20 references indexed in Scilit:
- Large-Scale Generation of Natural Killer Lymphocytes for Clinical ApplicationJournal of Hematotherapy & Stem Cell Research, 2002
- The Biology of Natural Killer Cells and Implications for Therapy of Human DiseaseJournal of Hematotherapy & Stem Cell Research, 2001
- Cellular Therapy of Cancer with Natural Killer Cells: Will It Ever Work?Journal of Hematotherapy & Stem Cell Research, 2001
- Detection of microchimerism by PCR is a function of amplification strategyTransfusion, 2001
- A SYNERGISTIC INCREASE IN TRANSPLANTABLE PERIPHERAL BLOOD STEM CELLS IN MICE BY CO-ADMINISTRATION OF RECOMBINANT HUMAN INTERLEUKIN 6 AND RECOMBINANT HUMAN GRANULOCYTE COLONY-STIMULATING FACTORTransplantation, 1995
- Immunotherapy with interleukin-2 (IL2) and lymphokine-activated natural killer cells: Improvement of clinical responses in metastatic renal cell carcinoma patients previously treated with IL2European Journal Of Cancer, 1994
- Human renal‐cell carcinoma cells are able to activate natural killer cellsInternational Journal of Cancer, 1992
- Rapid HLA‐DRB1 genotyping by nested PCR amplificationTissue Antigens, 1992
- Observations on the Systemic Administration of Autologous Lymphokine-Activated Killer Cells and Recombinant Interleukin-2 to Patients with Metastatic CancerNew England Journal of Medicine, 1985
- Kinetics of indium-III labelled lymphocytes in normal subjects and patients with Hodgkin's disease.BMJ, 1977